Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?

Key Points Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical company's management is taking active steps to counter some longstanding headwinds. This is a great stock for income-focused investors, but it's also appealing to growth-minded investors. 10 stocks we like better than Bristol Myers Squibb › With a forward yield nearing 4%, Bristol Myers Squibb (NYSE: BMY) may seem like a great income buy among pharmaceutical stocks. Alongside a moderately high yield, this healthcare stock also has a nearly 20-year dividend growth track record, and trades at a low valuation.